Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Truist Financial Remains a Buy on Cormedix (CRMD)
Leerink Partners Initiates Coverage On Cormedix With Outperform Rating, Announces Price Target of $18
Leerink Partners Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $18
Cormedix Analyst Ratings
Cormedix Analyst Ratings
D. Boral Capital Initiates Coverage On Cormedix With Buy Rating, Announces Price Target of $15
D. Boral Capital Initiates CorMedix(CRMD.US) With Buy Rating, Announces Target Price $15
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix (CRMD) Receives a Buy From Truist Financial
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $18
Cormedix Buy Rating: Strong Sales Performance and Expanding Customer Base Signal Positive Growth Prospects
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
RBC Capital Maintains Outperform on Cormedix, Raises Price Target to $12
Cormedix Analyst Ratings
JMP Securities Maintains CorMedix(CRMD.US) With Buy Rating, Maintains Target Price $19
Truist Financial Maintains CorMedix(CRMD.US) With Buy Rating
Cormedix Analyst Ratings
Needham Maintains CorMedix(CRMD.US) With Buy Rating, Raises Target Price to $18